TOKYO (Reuters) - Japan's Takeda Pharmaceutical Co Ltd 4502.T on Wednesday forecast operating profit to grow 16 percent in the current fiscal year on strong sales of drugs like cancer treatment Ninlaro and bowel disease drug Entyvio.
The company’s outlook for an operating profit of 180 billion yen ($1.58 billion) in the year to March 31, 2018, was below an average forecast of 197.7 billion yen from 15 analysts surveyed by Thomson Reuters.
Takeda reported a 19 percent rise in operating profit for the year just ended to 155.87 billion yen.
Reporting by Sam Nussey; Editing by Randy Fabi
Our Standards: The Thomson Reuters Trust Principles.